Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Articles

Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors

Garrett M. Frampton, Siraj M. Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M. Bauer, Mikhail Akimov, Jose A. Bufill, Carrie Lee, David Jentz, Rick Hoover, Sai-Hong Ignatius Ou, Ravi Salgia, Tim Brennan, Zachary R. Chalmers, Savina Jaeger, Alan Huang, Julia A. Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle A. Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M. Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S. Ross, Eric Collisson, Malte Peters, Philip J. Stephens and Vincent A. Miller
Garrett M. Frampton
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gframpton@foundationmedicine.com
Siraj M. Ali
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Rosenzweig
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juliann Chmielecki
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinyuan Lu
2Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Todd M. Bauer
3Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikhail Akimov
4Novartis Pharma AG, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose A. Bufill
5Michiana Hematology-Oncology, PC, Mishawaka, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carrie Lee
6University of North Carolina School of Medicine, Clinical Research, Thoracic Oncology Program, Chapel Hill, North Carolina.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Jentz
7South Bend Medical Foundation, South Bend, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rick Hoover
7South Bend Medical Foundation, South Bend, Indiana.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sai-Hong Ignatius Ou
8Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Irvine, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravi Salgia
9The University of Chicago School of Medicine, Chicago, Illinois.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tim Brennan
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zachary R. Chalmers
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Savina Jaeger
10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Huang
10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia A. Elvin
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Erlich
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Fichtenholtz
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kyle A. Gowen
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Greenbowe
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adrienne Johnson
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Depinder Khaira
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caitlin McMahon
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric M. Sanford
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Roels
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jared White
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Greshock
10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Schlegel
10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doron Lipson
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roman Yelensky
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deborah Morosini
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey S. Ross
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Collisson
2Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malte Peters
4Novartis Pharma AG, Basel, Switzerland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip J. Stephens
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent A. Miller
1Foundation Medicine Inc., Cambridge, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2159-8290.CD-15-0285 Published August 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: May 2015 to January 2021

AbstractFull-text HTMLPDF
Total97812030814322

Cited By

Article Information

Volume 5, Issue 8, pp. 850-859

DOI 
https://doi.org/10.1158/2159-8290.CD-15-0285
PubMed 
25971938

Published By 
American Association for Cancer Research
Print ISSN 
2159-8274
Online ISSN 
2159-8290
History 
  • Received March 11, 2015
  • Revision received May 7, 2015
  • Accepted May 11, 2015
  • Published first May 13, 2015.

Article Versions

  • Previous version (May 13, 2015 - 06:52).
  • Previous version (June 24, 2015 - 07:12).
  • Previous version (July 17, 2015 - 10:42).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2015 American Association for Cancer Research.

Author Information

  1. Garrett M. Frampton1,*,
  2. Siraj M. Ali1,
  3. Mark Rosenzweig1,
  4. Juliann Chmielecki1,
  5. Xinyuan Lu2,
  6. Todd M. Bauer3,
  7. Mikhail Akimov4,
  8. Jose A. Bufill5,
  9. Carrie Lee6,
  10. David Jentz7,
  11. Rick Hoover7,
  12. Sai-Hong Ignatius Ou8,
  13. Ravi Salgia9,
  14. Tim Brennan1,
  15. Zachary R. Chalmers1,
  16. Savina Jaeger10,
  17. Alan Huang10,
  18. Julia A. Elvin1,
  19. Rachel Erlich1,
  20. Alex Fichtenholtz1,
  21. Kyle A. Gowen1,
  22. Joel Greenbowe1,
  23. Adrienne Johnson1,
  24. Depinder Khaira1,
  25. Caitlin McMahon1,
  26. Eric M. Sanford1,
  27. Steven Roels1,
  28. Jared White1,
  29. Joel Greshock10,
  30. Robert Schlegel10,
  31. Doron Lipson1,
  32. Roman Yelensky1,
  33. Deborah Morosini1,
  34. Jeffrey S. Ross1,
  35. Eric Collisson2,
  36. Malte Peters4,
  37. Philip J. Stephens1 and
  38. Vincent A. Miller1
  1. 1Foundation Medicine Inc., Cambridge, Massachusetts.
  2. 2Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California.
  3. 3Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee.
  4. 4Novartis Pharma AG, Basel, Switzerland.
  5. 5Michiana Hematology-Oncology, PC, Mishawaka, Indiana.
  6. 6University of North Carolina School of Medicine, Clinical Research, Thoracic Oncology Program, Chapel Hill, North Carolina.
  7. 7South Bend Medical Foundation, South Bend, Indiana.
  8. 8Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Irvine, California.
  9. 9The University of Chicago School of Medicine, Chicago, Illinois.
  10. 10Novartis Institutes for BioMedical Research, Cambridge, Massachusetts.
  1. ↵*Corresponding Author:
    Garrett M. Frampton, Foundation Medicine Inc., 150 Second Street, Cambridge, MA 02141. Phone: 617-418-2200; Fax: 617-418-2201; E-mail: gframpton{at}foundationmedicine.com
View Full Text
PreviousNext
Back to top
Cancer Discovery: 5 (8)
August 2015
Volume 5, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton, Siraj M. Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M. Bauer, Mikhail Akimov, Jose A. Bufill, Carrie Lee, David Jentz, Rick Hoover, Sai-Hong Ignatius Ou, Ravi Salgia, Tim Brennan, Zachary R. Chalmers, Savina Jaeger, Alan Huang, Julia A. Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle A. Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M. Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S. Ross, Eric Collisson, Malte Peters, Philip J. Stephens and Vincent A. Miller
Cancer Discov August 1 2015 (5) (8) 850-859; DOI: 10.1158/2159-8290.CD-15-0285

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton, Siraj M. Ali, Mark Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M. Bauer, Mikhail Akimov, Jose A. Bufill, Carrie Lee, David Jentz, Rick Hoover, Sai-Hong Ignatius Ou, Ravi Salgia, Tim Brennan, Zachary R. Chalmers, Savina Jaeger, Alan Huang, Julia A. Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle A. Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M. Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S. Ross, Eric Collisson, Malte Peters, Philip J. Stephens and Vincent A. Miller
Cancer Discov August 1 2015 (5) (8) 850-859; DOI: 10.1158/2159-8290.CD-15-0285
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Methods
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • YTHDF2 Maintains Glioblastoma Stem Cells
  • Genomic Profiling in FGFR2-Rearranged Cholangiocarcinoma
  • Organoid Platform for Developing Ovarian Cancer Therapies
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement